Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1222174-93-7

Post Buying Request

1222174-93-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1222174-93-7 Usage

General Description

5-bromo-1-methyl-1H-pyrazole-3-carboxylic acid is a chemical compound with the molecular formula C6H6BrN3O2. It is a pyrazole derivative and contains a bromine atom, a methyl group, and a carboxylic acid functional group. 5-broMo-1-Methyl-1H-pyrazole-3-carboxylic acid has potential applications in the field of pharmaceuticals, agrochemicals, and material science. It may be used as a building block in the synthesis of various organic compounds and may possess biological activity, making it of interest for drug discovery and development. Its chemical properties and potential applications make it a subject of interest for further study and research in various fields of science and technology.

Check Digit Verification of cas no

The CAS Registry Mumber 1222174-93-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,2,1,7 and 4 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1222174-93:
(9*1)+(8*2)+(7*2)+(6*2)+(5*1)+(4*7)+(3*4)+(2*9)+(1*3)=117
117 % 10 = 7
So 1222174-93-7 is a valid CAS Registry Number.

1222174-93-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-bromo-1-methylpyrazole-3-carboxylic acid

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1222174-93-7 SDS

1222174-93-7Relevant articles and documents

Synthesis method of 5-bromine-1-methyl-1H-pyrazole-3-amine

-

Paragraph 0015, (2020/12/30)

The invention discloses a synthesis method of 5-bromine-1-methyl-1H-pyrazole-3-amine. The method comprises the steps of condensing diethyl butynedioate serving as a raw material with methylhydrazine to obtain 5-hydroxyl-1-methyl-1H-pyrazole-3-carboxylic acid ethyl ester, and reacting the 5-hydroxyl-1-methyl-1H-pyrazole-3-carboxylic acid ethyl ester with phosphorus oxybromide to obtain 5-bromine-1-methyl-1H-pyrazole-3-carboxylic acid ethyl ester; hydrolyzing in a sodium hydroxide alcohol solution to obtain 5-bromine-1-methyl-1H-pyrazole-3-carboxylic acid, reacting the 5-bromine-1-methyl-1H-pyrazole-3-carboxylic acid with dimethyl azide phosphate and tert-butyl alcohol to obtain tert-butyl (5-bromine-1-methyl-1H-pyrazole-3-yl) carbamate, and hydrolyzing in trifluoroacetic acid to obtain the5-bromine-1-methyl-1H-pyrazole-3-amine. The method has the advantages of simple synthesis route, reasonable process selection, low raw material cost, simple and easily available raw materials, convenient operation and post-treatment, and no use of highly toxic reagents, and overcomes the defects of expensive and unavailable raw materials, unsafe operation, difficult amplification and the like in the existing synthesis process.

PYRAZOLYL-BASED CARBOXAMIDES V

-

, (2016/04/20)

The invention relates to pyrazolyl-based carboxamlde compounds of formula (I) useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES

-

Paragraph 0179-0180, (2014/03/26)

Disclosed are compounds of Formula (1), and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1222174-93-7